MedTrace Logo

Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients

NCT01073644 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 3

Last updated 2013-07-04

No results posted yet for this study

Summary

The primary purpose is to monitor the safety and tolerability and effectiveness of sunitinib malate in the treatment of patients with metastatic renal cell carcinoma and gastrointestinal stromal tumor among filipino patients in usual clinical practice setting.

Conditions

  • Metastatic Renal Cell Carcinoma

Interventions

DRUG

Sunitinib malate

sunitinib 50 mg, 4 weeks on, 2 weeks off

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2010-04-30
Completion
2010-04-30

Countries

  • Philippines

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01073644 on ClinicalTrials.gov